Hengrui Medicine: First repurchase of 0.004% of the company's shares, with a total transaction amount of 18.31 million yuan.

Hetior Pharmaceuticals announced that the company repurchased 270,000 A shares for the first time on September 4, 2025, accounting for 0.004% of the total share capital, with a transaction price ranging between 67.75 yuan/share and 67.97 yuan/share. The total amount paid was 18.3139 million yuan. This repurchase was used to implement the A-share employee stock ownership plan, with a repurchase price not exceeding 90.85 yuan/share, and an expected amount between 1 billion yuan and 2 billion yuan.